Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Key Stats

• Today's Range: $10.23 to $10.60
• 50-Day Range: $7.78 to $14.26
• 52-Week Range: $6.50 to $39.50
• Volume: 26,246 shs
• Average Volume: 104,478 shs
• Market Capitalization: $60.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.67
• Consensus Rating: Moderate Buy

Atara Biotherapeutics Stock Analysis - MarketRank™

Atara Biotherapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 257th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Atara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Atara Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Atara Biotherapeutics are expected to decrease in the coming year, from ($12.12) to ($15.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atara Biotherapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atara Biotherapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.95% of the float of Atara Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Atara Biotherapeutics has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Atara Biotherapeutics has recently increased by 4.72%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atara Biotherapeutics does not currently pay a dividend.

Dividend Growth

Atara Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.87

Percentage of Shares Shorted

12.95% of the float of Atara Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Atara Biotherapeutics has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Atara Biotherapeutics has recently increased by 4.72%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.45

News Sentiment

Atara Biotherapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Atara Biotherapeutics this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for ATRA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $45,114.00 in company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Atara Biotherapeutics is held by insiders.

Percentage Held by Institutions

70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATRA Stock Analysis - Frequently Asked Questions

How have ATRA shares performed this year?

Atara Biotherapeutics' stock was trading at $12.82 at the beginning of 2024. Since then, ATRA shares have decreased by 18.3% and is now trading at $10.47.
View the best growth stocks for 2024 here.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating analysts' consensus estimates of ($3.77) by $0.84. The biotechnology company had revenue of $40.19 million for the quarter, compared to analysts' expectations of $23 million.

When did Atara Biotherapeutics' stock split?

Atara Biotherapeutics's stock reverse split on Thursday, June 20th 2024. The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Atara Biotherapeutics' major shareholders?

Top institutional investors of Atara Biotherapeutics include Vestal Point Capital LP (2.54%), Geode Capital Management LLC (0.81%), Centiva Capital LP (0.75%) and FMR LLC (0.51%). Insiders that own company stock include Anhco Nguyen, Pascal Touchon, Eric J Hyllengren, Jill Henrich, Carol Giltner Gallagher, Jakob Dupont, Amar Murugan, William K Heiden and Utpal Koppikar.
View institutional ownership trends.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Agenus (AGEN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Athersys (ATHX), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATRA
• CUSIP: N/A
• CIK: 1604464
• Web: www.atarabio.com
• Phone: (805) 623-4211
• Fax: N/A
• Employees: 165
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.67
• High Stock Price Target: $21.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +59.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($25.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-276,130,000.00
• Net Margins: -132.58%
• Pretax Margin: -132.56%
• Return on Equity: N/A
• Return on Assets: -90.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.59
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $100.44 million
• Price / Sales: 0.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($24.34) per share
• Price / Book: -0.43

Miscellaneous

• Outstanding Shares: 5,760,000
• Free Float: 5,547,000
• Market Cap: $60.25 million
• Optionable: Optionable
• Beta: 0.55